Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.280
-0.010 (-0.78%)
At close: Mar 9, 2026, 4:00 PM EDT
1.250
-0.030 (-2.34%)
After-hours: Mar 9, 2026, 6:29 PM EDT

Revelation Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Net Income
-8.91-15.04-0.12-10.83-11.99
Upgrade
Depreciation & Amortization
0.030.030.030.030.02
Upgrade
Loss (Gain) From Sale of Assets
0.01----
Upgrade
Stock-Based Compensation
0.60.190.160.30.47
Upgrade
Other Operating Activities
0.02-0.08-8.330.010.05
Upgrade
Change in Accounts Payable
-0.21-0.580.75-0.67-0.27
Upgrade
Change in Other Net Operating Assets
0.2-2.850.23-0.060.63
Upgrade
Operating Cash Flow
-8.27-18.32-7.29-11.22-11.09
Upgrade
Capital Expenditures
--0.02---0.13
Upgrade
Investing Cash Flow
--0.02---0.13
Upgrade
Short-Term Debt Issued
---2.5-
Upgrade
Total Debt Issued
---2.5-
Upgrade
Short-Term Debt Repaid
----2.5-
Upgrade
Long-Term Debt Repaid
----0.8-
Upgrade
Total Debt Repaid
----3.3-
Upgrade
Net Debt Issued (Repaid)
----0.8-
Upgrade
Issuance of Common Stock
12.4712.8514.0311.720.6
Upgrade
Repurchase of Common Stock
----7.65-
Upgrade
Other Financing Activities
---11.92-
Upgrade
Financing Cash Flow
12.4712.8514.0315.28
Upgrade
Net Cash Flow
4.2-5.496.743.98-3.22
Upgrade
Free Cash Flow
-8.27-18.34-7.29-11.22-11.22
Upgrade
Free Cash Flow Per Share
-13.32-1283.18---
Upgrade
Levered Free Cash Flow
-4.97-8.34-4.11-3.66-6.71
Upgrade
Unlevered Free Cash Flow
-4.97-8.34-4.11-3.66-6.71
Upgrade
Change in Working Capital
-0.01-3.420.98-0.730.36
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.